KLRS

$KLRS chatter on StockTwits

• 
  George@Orlandotrader5d

  $KLRS Kalaris also confirms that its Phase 1b/2 multiple ascending dose study of TH103 for neovascular Age-related Macular Degeneration is actively enrolling and dosing patients. The company remains on-track to share initial data from the study in 1H 2027 which is designed to accelerate TH103's clinical development and inform dose selection for potential future Phase 3 development. Dead money till 2027

  View on StockTwits ↗
• 
  jorge .miguel@focafoca99Jun 4

  $KLRS saw its shareholders elect three new directors and ratify its auditor at the 2026 annual meeting.

  View on StockTwits ↗
• 
  George@OrlandotraderMay 27

  $KLRS Actually a Fund Purchase of Million Four where a Director of Kalaris has voting power. I’ll Take it.

  View on StockTwits ↗
• 
  Justin@YouVSYouMay 26

  💰 Top Insider Buys AHs 🔹 $KLRS — Director loaded 244,300 shares at $4.83~$1.18M buy. Biggest size on the board. 🔹 $TWFG — Director bought 33,283 shares at $18.64~$620K insider scoop. 🔹 $MKTW — 10% owner Frank Stansberry added 20,100 shares at $17.21~$346K conviction buy. 🔹 $AAT — Executive Chairman grabbed 10,000 shares at $22.67~$226K direct confidence. 🔹 $CRT — 10% owner added 18,902 shares at $10.87~$205K insider buy.

  View on StockTwits ↗
• 
  Scout@BecauseOfScoutBullishApr 30

  $KLRS Notice of EFFECT filed 2 weeks ago — $10 warrants are now active. Expecting investors to start buying these cheap shares. Starter position.

  View on StockTwits ↗
• 
  NOTRELOAD AI@notreload_aiApr 16

  $KLRS gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients. https://notreload.xyz/xy/morgan-stanley-sees-big-potential-in-kalaris-eye-drug-th103/

  View on StockTwits ↗
• 
  Quantumup@QuantumupApr 16

  Morgan Stanley🏁 $KLRS and said: We initiate coverage of KLRS with an Overweight rating and a $14 price target. $EYPT $OCUL REGN RHHBY Here's what else Morgan Stanley had to say in its initiation report: https://x.com/Quantumup1/status/2044764520149651643?s=20

  View on StockTwits ↗
• 
  jorge .miguel@focafoca99Apr 11

  $KLRS said CFO Matthew Gall will step down on April 14, with chief accounting officer Brett Hagen taking over as principal financial officer.

  View on StockTwits ↗
• 
  SuperGreenToday@SuperGreenTodayApr 7

  $KLRS

  View on StockTwits ↗
• 
  Apollo@ApolloAlertsBullishMar 19

  $KLRS

  View on StockTwits ↗
• 
  George@OrlandotraderMar 3

  $KLRS Come to PaPa

  View on StockTwits ↗
• 
  Billioner@BillionerOfKingFeb 24

  $KLRS Current Stock Price: $10.76

  View on StockTwits ↗
• 
  SE@outlawinvestor1BullishFeb 24

  @ELNINA thanks for flagging. i may invest. $KLRS th103 could potentially solve the treatment frequency burden seen with existing treatments, but in a more clever way compared to other next-gen approaches like $OCUL or $FDMT. one watchout is the intraocular inflammation that arose in ph1a study. it sounds like they may have fixed this issue, but if this comes up again in their ongoing ph1b/2 study, this may be a no-go for big pharma acquirers. at current fdmc ($280M) with ~$120M cash with multiple reputable biotech funds (including srinivas' samsara), i think i may place a bet on this one. they will be presenting more data from their ph1a this week at a conference so will keep an eye out for updates there.

  View on StockTwits ↗
• 
  nino@ELNINAFeb 24

  @outlawinvestor1 I have looked at your input about ALMS before, but i am wondering about the 2 tickers : ir.annexonbio.com/news-releases/news-release-details/annexon-host-person-and-virtual-kol-event-discuss-vonaprument in also KLRS https://kalaristx.com/#our-science I knew AKKARAJU SRINIVAS bought millions in $ALMS he just also bought in $KLRS , Your input please ?

  View on StockTwits ↗
• 
  Char@char13Feb 19

  $KLRS more than 100m market cap and a director bot a massive stake recently

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.